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CrU Editing of Neurofibromatosis 1 mRNA Occurs in Tumors That
Express Both the Type II Transcript and apobec-1, the Catalytic Subunit of
the Apolipoprotein B mRNA–Editing Enzyme
Debnath Mukhopadhyay,1 Shrikant Anant,1 Robert M. Lee,1 Susan Kennedy,1 David Viskochil,3
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CrU RNA editing of neurofibromatosis 1 (NF1) mRNA changes an arginine (CGA) to a UGA translational stop
codon, predicted to result in translational termination of the edited mRNA. Previous studies demonstrated varying
degrees of CrU RNA editing in peripheral nerve–sheath tumor samples (PNSTs) from patients with NF1, but the
basis for this heterogeneity was unexplained. In addition, the role, if any, of apobec-1, the catalytic deaminase that
mediates CrU editing of mammalian apolipoprotein B (apoB) RNA, was unresolved. We have examined these
questions in PNSTs from patients with NF1 and demonstrate that a subset (8/34) manifest CrU editing of RNA.
Two distinguishing characteristics were found in the PNSTs that demonstrated editing of NF1 RNA. First, these
tumors express apobec-1 mRNA, the first demonstration, in humans, of its expression beyond the luminal gastro-
intestinal tract. Second, PNSTs with CrU editing of RNA manifest increased proportions of an alternatively spliced
exon, 23A, downstream of the edited base. CrU editing of RNA in these PNSTs was observed preferentially in
transcripts containing exon 23A. These findings were complemented by in vitro studies using synthetic RNA
templates incubated in the presence of recombinant apobec-1, which again confirmed preferential editing of tran-
scripts containing exon 23A. Finally, adenovirus-mediated transfection of HepG2 cells revealed induction of editing
of apoB RNA, along with preferential editing of NF1 transcripts containing exon 23A. Taken together, the data
support the hypothesis that CrU RNA editing of the NF1 transcript occurs both in a subset of PNSTs and in an
alternatively spliced form containing a downstream exon, presumably an optimal configuration for enzymatic
deamination by apobec-1.
Introduction
Neurofibromatosis type 1 (NF1 [MIM 162200]) is a
dominantly inherited disease affecting ∼1/3,500 individ-
uals worldwide. The NF1 gene has been mapped and
characterized extensively, and several features of interest
have emerged in relation to its altered function in dis-
ease. The NF1 gene spans ∼350 kb on chromosome
17q11.2 and encodes 60 exons, which are ubiquitously
transcribed (Li et al. 1995). The nuclear NF1 transcript
is ∼11 kb and encodes neurofibromin, a tumor-sup-
pressor–gene product of 2,818 residues, which contains
a region of ∼366 amino acids that functions as aGTPase-
activating protein (GAP) (reviewed in Cichowski and
Jacks 2001). GAP activity has been demonstrated for
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neurofibromin—more specifically, in the context of Ras
activation, both in vitro and in vivo—and is postulated
to be an important feature of the loss of function ac-
companying mutations in the NF1 gene (Basu et al.
1992; DeClue et al. 1992; Nakafuku et al. 1993; Bollag
et al. 1996; Guha et al. 1996; Lau et al. 2000; Sherman
et al. 2000).
Although the disorder becomes fully penetrant at a
relatively early age, the clinical features of NF1 are quite
variable even between affected siblings. In addition, as
many as half of the newly diagnosed cases of NF1 rep-
resent new mutations, a feature likely accounted for by
the high spontaneous-mutation rate at this locus (An-
dersen et al. 1993; Ars et al. 2000). Taken together, the
range of mutations and the phenotypic variability sug-
gest that modifier genes may play a significant role in
the natural history of this disease (Skuse and Ludlow
1995). An important consideration in understanding the
potential mechanisms for exerting phenotypic variabil-
ity in this disease is the role of RNA processing of tran-
scripts arising from somatic and germline mutations in
the NF1 gene; for example, alterations in mRNA splic-
ing have been demonstrated to occur in ∼50% of pa-
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tients with NF1 (Park and Pivnick 1998), suggesting an
important mechanism for amplifying the phenotypic
variability alluded to above.
Another posttranscriptional mechanism, CrU editing
of RNA,was postulated for inactivation of theGAP func-
tion of NF1 some years ago, by Skuse and colleagues
(Skuse et al. 1996; Skuse and Cappione 1997). These
investigators identified a CrU change, occurring at nt
3916 in the NF1 transcript, that changes a genomically
templated arginine (CGA) to a UGA stop codon in the
edited mRNA (Skuse et al. 1996; Skuse and Cappione
1997). The edited transcript encodes a truncated protein
product that terminates in the amino-terminal portion of
the GAP-related domain and would thus result in func-
tional inactivation of the tumor-suppressor function of
neurofibromin (Skuse et al. 1996; Ashkenas 1997; Cap-
pione et al. 1997; Skuse and Cappione 1997). Never-
theless, certain features of these original findings were
unexplained. The level of CrU editing of NF1 RNA, for
example, was quite variable (4%–17%) among the tu-
mors examined, with a trend suggesting that the more
malignant tumors demonstrated higher levels of editing
(Skuse et al. 1996; Skuse and Cappione 1997). In ad-
dition, the enzymatic factors mediating this CrU change
were not identified, and the relationship, if any, to editing
of intestinal apolipoprotein B (apoB) (APOB [MIM
107730]) mRNA, the prototype example of CrU de-
amination of nuclear RNA, was not resolved. In partic-
ular, CrU editing of mammalian intestinal apoB RNA
demonstrates absolute dependence on the expression of
the catalytic deaminase, apobec-1 (APOBEC-1 [MIM
600130]) (Hirano et al. 1996; Morrison et al. 1996),
whereas preliminary studies by Skuse et al. (1996) re-
vealed no clear evidence that apobec-1 plays a role in the
editing of NF1 RNA.
We have reexamined these questions through analysis
of peripheral nerve–sheath tumor samples (PNSTs) from
34 patients with NF1. The majority, 26 of 34, of tumors
demonstrated low levels of CrU RNA editing, in the
range of 0%–2.5%, with 10 of these 26 demonstrating
!1% editing, the limits of reliable detection of the assay.
However, the remaining 8 of the 34 tumors demon-
strated 3%–12% CrU editing of NF1 RNA, which was
reproducible and validated by sequencing of the cDNA
products. These tumors demonstrated two distinguish-
ing characteristics. First, these PNSTs express apobec-
1 mRNA, the catalytic deaminase of the holoenzyme
that edits apoB RNA (Teng et al. 1993; Lau et al. 1994;
Yamanaka et al. 1994; Davidson and Shelness 2000),
suggesting an important role for apobec-1 in the context
of a target beyond apoB RNA. Second, NF1 RNA from
these PNSTs contains increased proportions of an al-
ternatively spliced exon, 23A, downstream of the edited
base in which editing occurs preferentially. These find-
ings, together with results of both in vivo and in vitro
experiments with apobec-1, strongly suggest an impor-
tant mechanistic linkage between NF1 RNA splicing
and CrU editing and provide a basis for understanding
the heterogeneity of posttranscriptional regulation of
NF1 expression.
Material and Methods
Tissue Procurement
The use of human tumor and normal adjacent tissue
in this investigation was reviewed and approved by the
institutional review boards of the University of Chicago
Hospitals, the University of UtahHospital,Massachusetts
General Hospital, Harvard University Hospital, and
Washington University School of Medicine. Samples of
PNSTs were collected from a total of 34 patients with
NF1, whose clinical diagnosis was based on National In-
stitutes of Health consensus-conference criteria (National
Institutes of Health Consensus Development Conference
1988). No attempt was made to identify familial versus
sporadic cases. In addition, paired normal and tumor sam-
ples were obtained from 11 patients (without NF1) un-
dergoing surgical resection for colon adenocarcinoma.
The majority of these samples were moderately differ-
entiated tumors located in the proximal, mid, or descend-
ing colon. Each was snap-frozen in liquid nitrogen and
was stored at 80C until processed. Frozen tissue sec-
tions were stained with hematoxylin and eosin to confirm
the histological composition of these specimens.
Endogenous Editing of NF1 mRNA
Total RNA and genomic DNA from the NF1 and
colon-cancer tissues was isolated by TRIzol reagent
(LifeTechnologies). First-strand cDNA was synthesi-
zedby Superscript II reverse transcriptase (RT)
(LifeTechnologies) primed with random hexamers.
PCR was performed with Pyrococcus woesei DNA
polymerase (Roche Molecular Biochemicals), to am-
plify NF1 cDNA flanking the edited base (fig. 1), by
primers SA61 (5′- CAAGGAGAACTCCCTATAGCG-
ATG-3′; 5′ at nt 3650) and SA64 (5′-CTGTTCTGAGG-
GAAACGCTGG-3′; 5′ located at nt 4201). An aliquot
of each PCR was analyzed by agarose-gel electropho-
resis to monitor yield and the integrity of the product.
Typical yield was 0.4–0.5 mg/50 ml PCR. To selectively
amplify NF1 mRNA containing exon 23A, primer
RML33 (5′-TGTAGCTTTATTCAGTAGGGAGTGG-
CAAG-3′; 5′ located at nt 4142) was substituted for
SA64, in the PCR (fig. 1). To determine the proportions
of NF1 mRNA containing exon 23 A, 10 mCi a[32P]-
dCTP (3,000 Ci/mmol) was included in the reaction,
and the products were analyzed by 8% native PAGE
and were quantitated by phosphorimaging (Molecular
Dynamics). Genomic DNA corresponding to exon 22
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Figure 1 A, Organization of NF1. Top, Exons 21–24 of NF1, along with exon and intron sizes. The alternatively spliced exon 23A is
within the vertical brackets, and the corresponding region in NF1 mRNA is shaded. Identities, orientations, and locations of the various primers
are indicated above the exon and intron designations. Bottom, Alignment of 41-nt region (nt 3896–3936) of NF1 mRNA surrounding the
edited base, compared to human apoB mRNA (hapoB). The edited C in both sequences is indicated by an asterisk (*), and sequence identity
is indicated by vertical lines. The apobec-1 binding site and mooring sequence are indicated by horizontal brackets and a box, respectively. B,
apobec-1, a NF1 RNA–binding protein. UV cross-linking was performed by incubating 250 ng GST/APOBEC-1 with either a 550-nt [32P]-
labeled NF1 RNA (NF [lanes 1–4]) containing exon 23A (nt 3650–4201) or a 105-nt [32P]-labeled apoB RNA (apoB [lanes 5 and 6]), flanking
the edited base. After treatment with RNaseT1 and UV irradiation, the cross-linked products were analyzed by 10% SDS-PAGE. For competition
analysis, 50- (lane 3) and 100-fold (lane 4) excess of cold apoB RNA was added to the reaction. The results shown are representative of three
such experiments. Molecular-weight markers are indicated to the left of the gel, and the location of the cross-linked GST/APOBEC-1 band is
indicated by the arrow to the right of the gel.
was amplified by primers 23-1-5 (5′-AAAAACACGGT-
TCTATGTGAAAAG-3′, located in intron 22) and 23-
1-3 (5′-TTTGTATCATTCATTTTGTGTGTA-3′, lo-
cated in intron 23-1), located in the adjacent introns
(fig. 1). Primer-extension analysis was employed to de-
termine the extent of editing of NF1 RNA at nt 3916,
by primer SK1 (5′- CATGTTGCCAATCAGAGGAT-
GTG-3′, located at nt 3949) (Skuse et al. 1996), which
is complementary to a 23-nt region 12 nt downstream
of the edited base. The primer SK1 is that used by Skuse
et al. (1996). [32P]-labeled SK1 primer was annealed to
10 ng NF1 cDNA flanking the edited base. Primer ex-
tension was conducted in the presence of 0.05 mM each
of dATP, dCTP, and TTP and 1.6 mM ddGTP, in the
presence of T7 DNA polymerase. In this assay, the ra-
diolabeled primer extends to the first upstream C (at
nt 3916) and undergoes chain termination, giving an
extension product of 34 nt. If the C at nt 3916 is edited
to T, the products extend to the next upstream C, at
nt 3908, giving an extension product of 42 nt. The
primer-extension products were resolved by PAGEwith
10% acrylamide containing 8 M urea, followed by
phosphorimaging. We have validated and characterized
this assay extensively in the context of editing of apoB
RNA (Giannoni et al. 1994; Anant et al. 1998; Madsen
et al. 1999). Standardization of the assay was under-
taken by use of mixtures of NF1 cDNA containing
known quantities of C3916 and T3916 products from
sequence-validated templates constructed from previ-
ously amplified NF1 cDNA (550 bp), in which a T at
nt 3916 was introduced by mutagenesis. Known quan-
tities of PCR product were used to establish the optimal
conditions for primer extension. This established that
the reliable limits of detection with 10 ng template cor-
respond to 1% U (data not shown). Levels of apparent
editing !1% were considered background “primer read
through.” All assays included a C standard and a T
standard, for reference.
In Vitro RNA-Editing Assay
Synthetic templates were prepared to yield transcripts
that either included (550 nt) or did not include (487 nt)
exon 23A and that contained a C at nt 3916. A 20-fmol
sample of each RNA was individually incubated in a
buffer containing 20 mM HEPES. HCl pH 7.8, and 100
mM KCl, at 30C for 4 h, in the presence of 250 ng
glutathione-S-transferase (GST)/apobec-1 and 50 mg of
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Figure 2 NF1 mRNA undergoing CrU editing in a subset of neurofibromatosis-related PNSTs. A, Total RNA extracted from neurofi-
bromatosis tumor tissue—and extent of editing of NF1 mRNA, as determined by primer-extension assay as described in the “Material and
Methods” section. The primer-extension products were separated on a gel of 10% polyacrylamide containing urea and were autoradiographed.
A representation of experiments performed in triplicate for 34 neurofibromatosis tumor samples is shown. The locations of the primer (P) and
of unedited (C) and edited (T) primer-extension products are indicated to the right of the gel. B, CrU editing, which is shown not to be a
somatic mutation. Genomic DNA flanking exon 23-1 was amplified by PCR using intron-specific primers and subsequently was subjected to
primer-extension analysis. As controls, PCR products containing either C or T at nt 3916 of NF1 cDNA were also analyzed. The locations of
the primer (P) and of unedited (C) and edited (T) primer-extension products are indicated to the right of the gel. C, Editing at nt 3916 of NF1
RNA, confirmed by sequencing of individual cDNA clones. The locations of the unedited (Unedited C; top) and edited (Edited T; bottom)
nucleotide in a representative clone are indicated by arrows above the gels.
a 30% ammonium sulfate precipitate of bovine liver S-
100 extracts (MacGinnitie et al. 1995). The RNA was
extracted, subjected to primer extension with [32P]-la-
beled SK1 primer (see above), and subsequently ana-
lyzed, under denaturing conditions, by PAGE with 8%
polyacrylamide gel containing 8M urea. Editing of RNA
was quantitated by phosphorimager analysis (Molecular
Dynamics).
Protein-Truncation Assay
NF1 cDNA encoding exons 21–24 was amplified by
RT-PCR, as described above, with primers NF-PPT-5′ (5′-
GGGTGTAATACGACTCACTATAGGCCACCATGG-
AGCAGAAACTCATCTCTGAACAAGGAGAACTCC-
CTATAGCGATGGCTC-3′; T7 promoter is underlined,
and myc-tag is boldface italic) and SA64. NF-PTT-5′ was
designed to contain an upstream T7 promoter and a myc
epitope tag, in frame with the NF1 cDNA. These primers
were designed so that the region amplified contained the
same numbers of methionine residues in the translation
products from transcripts either with or without exon
23A. The full-length product (∼22 kD) contains six me-
thionine residues, whereas the truncated protein (∼11 kD)
contains five. The RT-PCR products were subjected to
coupled transcription-translation (Promega) with rabbit
reticulocyte lysates in the presence of translation-grade
[35S]-methionine (Amersham-Pharmacia), according to
the manufacturer’s recommendations. The translation re-
action was subsequently immunoprecipitated with anti-
myc monoclonal antibody 9E-10 (Santa Cruz Biotech-
nology) and was analyzed by gradient 10%–20% SDS-
PAGE and autoradiography.
Detection of apobec-1 and apobec-1
Complementation Factor (ACF) mRNA
RT-PCR was conducted by use of primers, listed be-
low, for apobec-1 and ACF. First-strand cDNA synthesis
was undertaken as described above, using random-hex-
amer priming; cDNA amplification used gene-specific
primers located in the 5′ and 3′ regions of the coding
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Table 1
CrU Editing of NF1 RNA in PNSTs
CATEGORY
AND SAMPLE
EDITING
(%) EXPRESSION
HISTOLOGY Mean SD Range ( )np 3 apobec-1 ACF
No editing (!1% U):
NF20 Plexiform .64 .34 .3–1.0  
NF22 Triton tumor .65 .35 .3–.9  
NF6 Neurofibroma .66 .43 .2–1.1  
NF35 Glioblastoma .68 .22 .45–.9  
NF21 Malignant schwannoma .69 .65 .2–1.3  
NF3 Neurofibroma .72 .65 .1–1.4  
NF4 Neurofibroma .72 .68 .1–1.5  
NF2 Neurofibroma .86 .65 .75–1.1  
NF18 Malignant schwannoma .95 .65 .9–1.3  
NF5 Neurofibroma .99 .56 .95–1.7  
NF7 Malignant schwannoma 1.01 .46 .9–1.5  
NF17 Neurofibroma 1.08 .24 .85–1.5  
NF13 Neurofibroma 1.14 .65 .75–1.8  
NF8 Malignant schwannoma 1.15 .75 .65–1.9  
NF16 Neurofibroma 1.15 .49 .55–1.7  
NF9 Neurofibroma 1.24 .43 .8–1.7  
NF27 Malignant schwannoma 1.35 .36 .9–1.7  
NF23 Neurofibroma 1.37 .54 .75–1.9  
Low editing (!2.5% U):
NF14 White matter 1.48 .39 1.0–1.9  
NF34 Glioblastoma 1.52 .43 1.1–1.95  
NF11 Neurofibroma 1.57 .54 1.0–2.1  
NF1 Neurofibroma 1.58 .58 1.0–2.2  
NF30 Ganglioneuroma 1.83 .16 1.65–2.1  
NF15 Peripheral nerve 1.85 .86 1.1–2.5  
NF31 Schwannoma 1.99 .38 1.5–2.5  
NF19 Neurofibroma 2.36 1.03 1.33–3.4  
NF10 Neurofibroma 3.16 .98 2.2–4.1  
NF33 Glioblastoma 3.18 .68 2.6–3.9  
NF26 Nonmalignant schwannoma 3.48 .62 2.8–4.2  
NF32 Neurofibroma 5.06 .89 4.1–5.9  
Bona-fide editing (13% U):
NF29 Granulomatous cell 5.52 1.08 4.3–6.7  
NF25 Malignant schwannoma 10.35 2.53 8.1–12.5  
NF24 Malignant schwannoma 12.02 3.12 8.9–15.3  
NF28 Ganglioneuroblastoma 12.65 1.65 10.5–14.8  
sequence. PCR cycling conditions for apobec-1 and ACF
were 95C for 3 min, 1 cycle; 95C for 30 s, 55C for
1 min, and 72C for 1 min, 30 cycles; and 72C for 10
min. As a control, glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) mRNA was simultaneously am-
plified by the indicated primers. The amplified products
were sequenced on both strands to confirm their identity.
Primers used are as follows: for GAPDH, primers 5′-
TCGGAGTCAACGGATTTGGTCG-3′ and GAP 5′-A-
GGCAGGGATGATGTTCTGGAGAG-3′; for apobec-
1, primers SA146 5′-GACGACGACAAGGGATCCAT-
GAGTTCCGAGACAGGC-3′ and SA147 5′-GGAACA-
AGACCCGTCGACTCATTTCAACCCTGTGGCCCA-
CAG-3′; and, for ACF, primers ACF2 5′-CTCGAGTCA-
GAAGGTGCCATATCCATC-3′ and ACF6 5′-CAGAT-
ATTAGAAGAGATTTGTC-3′. The primer pairs for
apobec-1 generate a full-length cDNA, whereas the
primers for ACF generate an amplicon of 447 bp. Where
indicated in the text, nested PCR was undertaken for
apobec-1, by use of the primers listed below, which yield
a product of 273 bp (nt 116–388). Primers used for
nested PCRwere as follows: JM-8 5′-ACCCCAGAGAA-
CTTCGTAAAGAGGCC-3′ and JM-9 5′-CCGAGCTA-
CGTAGATCACTAGAGTCA-3′.
UV Cross-Linking of NF1 and apoB RNAs to apobec-1
NF1 cDNA flanking the edited base (fig. 1) was am-
plified by primers SA61 and SA64, subcloned intoplasmid
pGEM-3zf() (Promega) and was sequenced to confirm
the presence of wild-type sequence. The plasmid was lin-
earized with restriction endonuclease KpnI and was sub-
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Figure 3 Protein-truncation assay. NF1 cDNA flanking the ed-
ited base was amplified by primers NF-PTT-5′ and SA64, as described
in the “Material and Methods” section. The RT-PCR products were
subjected to in vitro coupled transcription/translation in the presence
of [35S] methionine. The translation productswere immunoprecipitated
with a-myc-tag antibody and were resolved by 10%–20% SDS-PAGE.
The locations of the full-length (FL) and truncated (Tr) translation
products, which correspond to the unedited and edited NF1 mRNA,
respectively, are indicated to the left of the gel. Control reactions were
undertaken by use of a synthetic, sequence-validated template con-
taining either C or T at nt 3916. The results shown are representative
of three such experiments.
Figure 4 apobec-1 mRNA, expressed in a subset of neurofibro-
matosis tumors. RT-PCR by gene-specific primers (“” lanes) was
performed to amplify apobec-1, ACF, and GAPDH (top, middle, and
bottom, respectively). As a control, PCR without prior RT (“” lanes)
was performed. The locations of molecular-weight standards are in-
dicated to the right of the gel.
jected to in vitro transcriptionwith SP6 RNApolymerase,
in the presence of a[32P]-CTP (3,000 Ci/mmol). The [32P]-
labeled NF1 RNA (50,000 cpm, at 4# 108 cpm/mg) was
incubated with 25 ng recombinant GST/APOBEC-1
(MacGinnitie et al. 1995) for 15 min at room tempera-
ture, in a buffer containing 10 mM HEPES pH 8.0, 100
mM KCl, 1 mM EDTA, 0.25 mM DTT, and 2.5% glyc-
erol. The reaction was then sequentially treated with
RNase T1 (final concentration, 1 unit/ml) and heparin
(final concentration, 5 mg/ml), followed by UV irradi-
ation (250 mJ/cm2) in a Stratalinker (Stratagene). As
control, RNA binding was performed with a 105-nt rat
apoB RNA that previously had been demonstrated to
bind apobec-1 (Anant et al. 1995; Nakamuta et al. 1995;
Anant and Davidson 2000). Competition analysis was
performed with radiolabeled NF1 RNA and 5- and 10-
fold excess of cold apoB RNA, as described in detail
elsewhere (Anant et al. 1995).
Adenovirus-Mediated Infection of HepG2 Cells
Recombinant adenovirus expressing either rat apobec-
1 or a control, lacZ cDNA, were cloned as described
elsewhere (Kozarsky et al. 1996) and were titered to a
multiplicity of infection (MOI) of 109–1010 pfu/ml.
HepG2 cells were infected with 3 # 103–MOI recom-
binant adenovirus and cell lysates, and total RNA was
prepared for analysis after 48 h. Primer-extension anal-
ysis was performed to quantitate CrU editing of en-
dogenous NF1 and apoB RNA, as outlined above and
as described in detail elsewhere (Giannoni et al. 1994).
Cell lysates were analyzed by denaturing SDS-PAGE and
western blotting, to demonstrate, as described elsewhere
(Anant and Davidson 2000), the presence of apobec-1,
by rabbit anti–apobec-1 IgG.
Results
NF1 RNA Sequence Alignment Flanking the Edited
Base at nt 3916
The cis-acting elements regulating CrU editing of
apoB RNA have been extensively characterized and in-
clude an AU-rich bulk-RNA context, a mooring se-
quence 3′ of the edited base, and efficiency elements both
upstream and downstream (Shah et al. 1991; Backus and
Smith 1992; Driscoll et al. 1993; Backus et al. 1994;
Anant et al. 1995; Hersberger and Innerarity 1998; An-
ant and Davidson 2000). Alignment of an ∼40-nt stretch
of NF1 RNA sequence flanking nt 3916 reveals ∼50%
identity with apoB RNA, as has been noted elsewhere
(Skuse et al. 1996), including 6 of 11 matches in the
region corresponding to the mooring sequence (fig. 1).
More recently, a consensus apobec-1 binding motif,
UUUN[A/U]U, has been identified in both apoB RNA
and other validated targets of high-affinity binding by
apobec-1 (Anant and Davidson 2000). Further inspec-
tion of the NF1 RNA sequence flanking the edited base
reveals this consensus apobec-1 binding site immediately
upstream of the targeted cytidine (fig. 1). Therefore, we
examined directly the ability of recombinant apobec-1
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Figure 5 Editing of NF1 mRNA in colon cancers. A, Endoge-
nous editing of NF1 RNA, as determined by primer-extension analysis
and described in figure 2A. The data demonstrate increased editing in
colon tumor tissue (lanes T), compared to matched normal control
tissue (lanes N). In addition, no editing (!1% U) was observed in NF1
mRNA from normal brain (lane B), liver (lane L), or kidney (lane K).
B, apobec-1 mRNA expression induced in colon cancers. RT-PCRwas
performed in the presence of a[32P]-dCTP, by use of primers specific
for apobec-1 and GAPDH, to amplify a 274- and a 510-bp fragment,
respectively. Increased expression of apobec-1 is observed in colon
tumor tissue (lanes T), compared to paired normal tissue (lanes N).
The locations of the molecular-weight (in bp) markers are indicated
to the right of the gel.
to bind synthetic NF1 RNA template, using UV cross-
linking. The data demonstrate that apobec-1 binds NF1
RNA (fig. 1B) and that this binding is competed by apoB
RNA (fig. 1B, lanes 3 and 4).
CrU Editing of RNA of NF1 Samples
RNA from 34 PNSTs was subjected to primer-exten-
sion assay, to detect CrU editing of NF1 RNA, and the
reaction products were analyzed by urea PAGE and
phosphorimaging. A representative series of samples is
shown in figure 2A. Several of the samples (24, 25, and
28; see fig. 2A) demonstrated 12%–16% CrU editing
of RNA, similar to the values and range noted by Skuse
and colleagues (Skuse et al. 1996; Cappione et al. 1997).
However, having established, by using synthetic RNA
templates (data not shown), the limits of detection, we
were able to exclude bona fide editing in samples in
which there was less than ∼1% U (samples 20–22; see
fig. 2A). This technical point is also emphasized in the
results of primer-extension analysis of genomic DNA
from the most extensively edited tumors, in which there
is no detectable T in either of the sample lanes or in the
control C template (fig. 2B). Direct sequencing of the
cDNA products confirmed the presence of a T in the
edited cDNA, corresponding to nt 3916 (fig. 2C). The
cumulative results for the 34 samples assayed are listed
in table 1. The findings demonstrate that a subset (8/34)
of tumors manifest CrU editing of RNA (defined as
13% U) and that the remainder (26/34) demonstrate
either very low levels (1%–2.5% U [in the case of 16/
34]) or undetectable (!1% U [in the case of 10/34])
editing activity. These findings suggest that CrU editing
of NF1 RNA is not a universal finding in tumors but,
rather, appears to be confined to a subset of samples.
CrU Editing of NF1 RNA: Detection by
Protein-Truncation Assay
The products of the initial round of RT-PCR were
amplified in-frame with a myc-tag and T7 promoter and
were used to program a coupled in vitro transcription/
translation reaction mixture. Both full-length and trun-
cated products were recovered (fig. 3). The molar in-
corporation of [35S]-methionine into immunoprecipi-
table protein products revealed the observed proportion
of full-length to truncated protein products to be ∼10:
1, close to the value expected on the basis of CrU editing
(i.e., ∼10%–15%) of NF1 RNA in the respective sample
of origin.
Tumors Demonstrating CrU Editing: Expression of
apobec-1 mRNA
The expression of gene products associated with the
machinery for editing of apoB RNA was investigated as
a potential variable contributing to the heterogeneity ob-
served in CrU editing of NF1 RNA. Two gene products
in particular were examined. These correspond to apobec-
1, the catalytic deaminase responsible for CrU editing of
apoB, and ACF, the competence factor that supports site-
specific deamination of apoB RNA by apobec-1 (Teng et
al. 1993; Lellek et al. 2000; Mehta et al. 2000). apobec-
1 mRNA was detectable in all eight tumors that manifest
13% CrU editing (fig. 4 and table 1). In all cases, the
amplification products were sequenced, to confirm the
identity of apobec-1 (data not shown). Tumor samples
that demonstrated either no CrU editing (samples 21 and
22; see fig. 2A) or very low (i.e., ∼1%–2%) levels did
not yield a detectable product for apobec-1 mRNA (fig.
4 and table 1), even when nested PCR was used. More-
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Figure 6 Preferential editing of NF1 mRNA containing exon 23A. A, Levels of alternative splicing of exon 23A in various tumor samples,
as determined by RT-PCR and described in the “Material and Methods” section. As controls, PCRs were performed with synthetic RNA
templates either containing (23A) or lacking (23A) exon 23A. The results shown are representative of experiments performed in triplicate,
with all the tumor and normal samples. B, RT-PCR products of NF1 RNA containing (23A) and lacking (23A) the alternatively spliced
exon, which were purified by electrophoresis and which subsequently were subjected to primer-extension analysis. As a control, primer-extension
analysis was performed with cDNA templates containing only either a C or a T at nt 3916. The results shown are representative of three such
experiments. C, Correlation between editing of NF1 RNA and inclusion of exon 23A (data are percent of total amount). This correlation was
significant ( ).P ! .001
over, normal tissue from sites in which apobec-1 is not
detectable (e.g., liver, kidney, and brain) demonstrated
!1% CrU editing of NF1 RNA (fig. 5). The observation
that remains unexplained is the apparent lack of apobec-
1 expression in tumors demonstrating very low (i.e.,
∼1%–2%) levels CrU editing (fig. 4 and table 1). We
speculate that this findingmay be due to themixed cellular
composition typically found in the PNSTs, in which ed-
iting of NF1 RNA occurs in a small subset of cells and
in which apobec-1 mRNA is below detection limits. ACF
mRNA, by contrast, was detected in all samples (fig. 4
and table 1), a finding consistent with previous reports
that its expression is ubiquitous in humans (Lellek et al.
2000; Mehta et al. 2000). As an additional control, all
RNA samples supported amplification ofGAPDHmRNA
(fig. 4).
Non-Neuronal Tumors Expressing apobec-1 and
Demonstrating Editing of NF1 RNA
In humans, apobec-1 is normally confined to the lu-
minal gastrointestinal tract (Teng et al. 1993; Yamanaka
et al. 1994; Funahashi et al. 1995). Human colorectal
cancers, however, have been demonstrated to express
increased levels of apobec-1 mRNA, compared to nor-
mal adjacent mucosa (Lee et al. 1998). NF1 RNA was
amplified from these tumors as well as from the adjacent
normal tissue and was subjected to primer-extension as-
say. The results demonstrate higher levels of CrU editing
of RNA in the tumor samples (4%–8% U), compared
to paired normal tissue, and confirm the increase in apo-
bec-1 mRNA abundance (1%–3% U) (figs. 5A and B).
These findings suggest that CrU editing of NF1 RNA
is not confined to tumors arising from Schwann-like cells
but may be a feature of tumors that support apobec-1
expression; however, a more extensive survey of tumors
of the gastrointestinal tract will be required, to allow us
to formally examine the implications of editing of NF1
RNA, in relation to apobec-1–gene expression.
Editing of NF1 RNA: Occurrence in Transcripts
Containing Exon 23A
To further pursue the mechanisms underlying the het-
erogeneity of CrU editing of NF1, transcripts were se-
lectively amplified (by a strategy reviewed both in the
“Material and Methods” section and in fig. 1), to ex-
amine alternative splicing of exon 23A, downstream of
the edited base. As illustrated in figure 6A, these samples
reveal a range of proportions of this alternatively spliced
Figure 7 apobec-1 mediation of CrU editing of NF1 RNA. A, Assays of in vitro editing of RNA, performed with 20 fmol synthetic NF1
RNA either containing (23A) or lacking (23A) exon 23 A, in the presence of 250 ng recombinant GST/APOBEC-1 and 50 mg bovine liver
extract (Liv S100). After in vitro incubation, the RNA was extracted, and cDNA was prepared for analysis by primer extension (see the “Material
and Methods” section). The mobilities of the primer (P) and of the unedited (C) and edited (T) cDNA are indicated to the right of the gel. B,
Adenovirus-mediated expression of apobec-1. HepG2 cells, from a human hepatoma cell line, were infected with recombinant adenovirus
encoding either apobec-1 (Ad/apobec-1) or the bacterial b-galactosidase (Ad/lacZ). Forty-eight hours after infection, cell lysates were prepared
and were subjected to western blot analysis with rabbit a-apobec-1 IgG. Migration of the 27-kD apobec-1 immunoreactive band is indicated
by an arrow to the right of the gel, and molecular-weight standards are indicated to the left of the gel. C, Total RNA extracted from HepG2
cells infected with either Ad/apobec-1 or Ad/lacZ and subjected to RT-PCR for amplification of apoB (left panel) and NF1 (middle panel)
mRNAs flanking the edited base. Primer-extension analysis was performed and was analyzed by PAGE with 8% acrylamide containing urea.
To differentiate the editing of RNA in the two alternatively spliced NF1 transcripts (lanes23A), the PCR products were fractionated through
agarose gels, and the two products were isolated and were individually subjected to primer-extension analysis (right panel). The locations of
the primer and of unedited (C) and edited (U) primer-extension products, for both apoB and NF1, are indicated to the left or right of the gels.
This is a representative of three independent assays.
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exon. These amplicons were individually isolated and
were subjected to primer-extension analysis, and the ex-
tent of CrU editing was determined. As indicated in
figure 6B, CrU editing was found only in transcripts
containing exon 23A. This approach was applied to the
range of tumors studied, and the results demonstrated
a strong positive correlation between the relative pro-
portions of exon 23A–containing transcripts and the ex-
tent of CrU editing of RNA (fig. 6C). These findings
strongly suggest a functional relationship between the
presence of exon 23A and the editing of NF1 RNA.
apobec-1 as the Mediator of CrU Editing of NF1 RNA
In Vivo and In Vitro
We employed two complementary approaches to con-
firm the suspected role of apobec-1 in CrU editing of
NF1. In the first approach, we incubated synthetic NF1
transcripts that contained the unedited cytidine at nt
3916 and that either included (23A) or lacked (23A)
the alternatively spliced downstream exon, with apobec-
1 and S100 extracts. The results of these assays (fig. 7A)
reveal that CrU editing of NF1 RNA can be reproduced
in vitro and that transcripts containing exon 23A are
more extensively edited (12% 1.7% U; ), com-np 3
pared to transcripts lacking this alternatively spliced
exon (3.9% 0.8% U; ; ). In the secondnp 3 P ! .001
approach, we used adenovirus-mediated transduction of
apobec-1 to demonstrate a gain of function in cell cul-
ture. For this purpose, we turned to HepG2 cells, a hu-
man liver–derived cell line that expresses apoB RNA and
NF1 mRNA but that does not express endogenous apo-
bec-1 (Giannoni et al. 1994). HepG2 cells were infected
with either adenovirus apobec-1 or lacZ, and cell lysates
were prepared for protein and RNA extraction 48 h
later. The results confirm the efficient induction of ed-
iting of apoB RNA after introduction of apobec-1 (see
the western blot in fig. 7B) and reveal CrU editing at
the canonical site (nt 6666), as well as hyperediting of
upstream cytidines (C6661), as noted elsewhere (Sowden
et al. 1996; Yamanaka et al. 1996) (fig. 7C, left); RNA
from these same cells demonstrated CrU editing of NF1
RNA (fig. 7C, middle), with no such change, in either
transcript, after lacZ transfection. Further analysis of
these NF1 RNA species reveals that CrU editing was
detectable only in transcripts containing exon 23A (fig.
7C, right), confirming and extending findings from the
tumors analyzed above.
Discussion
Several mechanisms exist for amplification of the reper-
toire of genes encoded in chromosomal DNA. Posttran-
scriptional regulation encompasses one such level of con-
trol and includes editing of RNA, which has recently
emerged as an important restriction point in the species-
and tissue-specific modulation of gene expression (Maas
and Rich 2000). The central conclusion of the present
study demonstrates that CrU editing of NF1RNAoccurs
in a subset of tumor samples that have at least two dis-
tinguishing characteristics that distinguish them from
those tumors in which editing of RNA does not occur;
these characteristics are (1) the presence of apobec-1
mRNA and (2) the preferential inclusion of a downstream
exon, 23A, in the edited transcript. The findings (a) add
support to the hypothesis that, in the regulation ofmRNA
metabolism, apobec-1 may play a role beyond that of its
originally identified target, apoB, and (b) provide evidence
that alternative splicing of NF1 RNA may be an impor-
tant component of CrU editing of this transcript. Each
of these observations merits additional discussion.
apobec-1 is an RNA-specific cytidine deaminasewhose
expression, in humans, is confined to the luminal gas-
trointestinal tract (Hadjiagapiou et al. 1994; Lau et al.
1994). apobec-1 functions as a dimeric subunit compo-
nent of a multicomponent holoenzyme andmediates site-
specific deamination of a single cytidine in the nuclear
apoB transcript. This CrU RNA-editing reaction results
in the production of a truncated protein, apoB48, re-
quired for intestinal lipid transport (Chen et al. 1987;
Powell et al. 1987; Teng et al. 1993). Accordingly, the
finding that apobec-1 mRNA is expressed in neuronal
tumors from patients with NF1 represents the first dem-
onstration, in humans, of apobec-1 expression in cells
other than epithelial cells lining the gastrointestinal tract
(Hadjiagapiou et al. 1994; Lau et al. 1994). apobec-1
mRNA expression is widespread in the mouse and rat,
and CrU RNA editing activity can be demonstrated in
tissue extracts from numerous organs (Greeve et al. 1993;
Nakamuta et al. 1995; Hirano et al. 1997; Qian et al.
1997). Nevertheless, the mechanism by which apobec-1
expression is confined to the gastrointestinal tract in hu-
mans has not been clarified. Analyses undertaken by sev-
eral groups have revealed few informative features of the
proximal promoter region of the human APOBEC-1
gene, and no additional insight has been gained through
comparative analyses of the murine, rat, and human loci
(Greeve et al. 1993; Nakamuta et al. 1995; Hirano et al.
1997; Qian et al. 1997). apobec-1 mRNA expression has
been examined in a number of human carcinomas
(Greeve et al. 1999), in light of the phenotype associated
with forced overexpression of apobec-1 in transgenic an-
imals, in which promiscuous CrU RNA editing of other
target transcripts has been associated with hepatocellular
carcinoma (Yamanaka et al. 1996, 1997). These studies,
in human cancer tissues, concluded that apobec-1mRNA
is detectable only in cancers arising in the luminal gas-
trointestinal tract (Greeve et al. 1999), a finding that
previously had been noted in normal tissue (Greeve et al.
1993; Hadjiagapiou et al. 1994; Lau et al. 1994). Ac-
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cordingly, overexpression of apobec-1 does not appear
to be a general feature ofmalignancy; this said, the factors
that permit expression of apobec-1 mRNA in a subset
of PNSTs from patients with NF1 will require additional
investigation.
In considering the possibility that apobec-1 was in-
volved in CrU editing of NF1, we were intrigued by
the earlier observations, by Skuse and colleagues, that
the NF1 RNA region flanking the edited base contains
only ∼50% identity to the canonical apoB RNA se-
quence, particularly within an 11-nt motif referred to
as the “mooring sequence” (Backus and Smith 1992;
Skuse et al. 1996). We suspected, as did Skuse and col-
leagues, that this degree of mismatch would severely
impair the efficiency of CrU RNA editing (Skuse et al.
1996). This suspicion is consistent with the finding that
CrU editing of NF1 RNAproduces20%UGA (edited
RNA)—in contrast to the situation with intestinal apoB
mRNA, in which, typically, 190% exists in the UAA
(edited) form (Chen et al. 1987; Powell et al. 1987).
The mechanisms accounting for these quantitative dif-
ferences remain to be elucidated but include, in addition
to structural features of the transcript that are associ-
ated with the optimal nucleotide sequence, distinctive
requirements for trans-acting factors.
The functional significance, if any, of CrU editing of
NF1 RNA remains unresolved; in particular, it is widely
recognized that second-hit somatic mutations occur in
the wild-typeNF1 allele in many PNSTs in patients with
neurofibromatosis (reviewed in Cichowski and Jacks
2001). Furthermore, it should be emphasized that, with
the exception of CrT changes at nt 3916, we did not
systematically exclude somatic mutations in the PNSTs
investigated in this study; nevertheless, at least from a
theoretical standpoint, the finding that a subset of tu-
mors from patients with NF1 demonstrate CrU RNA
editing supports the hypothesis that modifier genes (in
this case, apobec-1) may play a role in the heterogeneity
of molecular defects. The corollary hypothesis is that
CrU editing of NF1 RNA creates a translational stop
codon, potentially leading to premature truncation of
neurofibromin. We attempted to demonstrate the pres-
ence of a truncated protein corresponding to the edited
mRNA in cell lysates from clonal intestinal-cancer cell
lines supporting 115% CrU editing, but we were suc-
cessful only in identifying the full-length form of the
protein (data not shown). Whether this reflects technical
limitations of the reagents or other explanations is cur-
rently unknown. Thus, the question of whether the ed-
ited NF1 RNA encodes a truncated protein in vivo is
still unresolved.
Studies of NF1 mRNA in affected patients have re-
vealed an∼50% incidence of splicing abnormalities (Park
and Pivnick 1998). The majority of these splicing defects
are predicted to result in protein truncations, and the
current findings are certainly consistent with this general
expectation; however, the results from this recent survey
of splicing abnormalities in NF1 failed to reveal any spe-
cific feature associated with exon 23A, nor was there any
particular clustering of alternative splice defects, which
would favor inclusion of this exon (Costa et al. 2001).
Exon 23A itself plays an important role in the function
of neurofibromin, as inferred from targeted deletion of
this region in mice, which results in a learning deficit
(Costa et al. 2001). These findings suggest that there may
be important parallels between the murine and human
genes for NF1, parallels that could be investigated with
surrogate models. Indeed, an important series of ques-
tions emerging from current studies concerns the possi-
bility that CrU editing of NF1 RNA may be experi-
mentally approached by murine models. This is an
attractive possibility, since our lab and others have gen-
erated mutant strains in which apobec-1 has been deleted
through homologous recombination. Additionally, the
auxiliary subunit of the enzyme that edits apoB RNA
recently has been cloned (Lellek et al. 2000; Mehta et al.
2000), and its role in alternative splicing andCrUediting
of NF1 RNA will be of interest. In this regard, studies
have demonstrated that an apobec-1–related RNA-spe-
cific deaminase, ADAR2, which mediates ArI editing of
double-stranded RNA, also plays a role in alternative
splicing (Rueter et al. 1999); this function will need to
be examined in the context of apobec-1 and NF1 RNA.
These and other issues related to the molecular mecha-
nisms of posttranscriptional regulation will be the focus
of future reports.
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